特宝生物
(688278)
| 流通市值：246.15亿 | | | 总市值：246.15亿 |
| 流通股本：4.07亿 | | | 总股本：4.07亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 545,302,286.89 | 2,100,322,880.68 | 1,459,790,700.44 | 903,579,420.87 |
| 营业收入 | 545,302,286.89 | 2,100,322,880.68 | 1,459,790,700.44 | 903,579,420.87 |
| 二、营业总成本 | 379,688,432.09 | 1,435,565,432.81 | 996,114,587.84 | 640,251,711.34 |
| 营业成本 | 37,765,345.01 | 140,054,360.83 | 93,618,306.63 | 63,822,877.66 |
| 税金及附加 | 2,793,828.13 | 11,236,531.13 | 7,910,851.59 | 4,827,403.14 |
| 销售费用 | 241,910,759.84 | 848,800,946.38 | 602,433,864.85 | 413,044,475.06 |
| 管理费用 | 54,393,514.08 | 210,309,264.02 | 152,367,240.5 | 83,075,768.6 |
| 研发费用 | 43,575,928.52 | 229,975,116.41 | 142,861,485.4 | 77,209,995.21 |
| 财务费用 | -750,943.49 | -4,810,785.96 | -3,077,161.13 | -1,728,808.33 |
| 其中:利息费用 | 114,113.69 | 506,172.56 | 371,362.41 | 249,633.98 |
| 其中:利息收入 | 975,134.82 | 6,627,012.19 | 4,789,912.14 | 3,113,302.14 |
| 加:公允价值变动收益 | - | 2,650,497.36 | 163,836.63 | 107,041.1 |
| 加:投资收益 | 1,396,404.36 | 3,547,176.5 | 2,258,410.95 | 1,895,625.91 |
| 资产处置收益 | 44,947.38 | 8,840.35 | 8,174.3 | 4,314.33 |
| 资产减值损失(新) | - | -12,759,590.36 | - | - |
| 信用减值损失(新) | 127,378.79 | -463,796.99 | -620,776.88 | -1,010,687.46 |
| 其他收益 | 3,332,991.92 | 22,979,904.14 | 15,198,230.69 | 4,312,865.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 170,515,577.25 | 680,720,478.87 | 480,683,988.29 | 268,636,869.17 |
| 加:营业外收入 | 501,719.03 | 453,064.21 | 279,605.27 | 243,141.94 |
| 减:营业外支出 | 13,649,430.31 | 40,519,054.91 | 33,291,682.43 | 22,223,638.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 157,367,865.97 | 640,654,488.17 | 447,671,911.13 | 246,656,372.87 |
| 减:所得税费用 | 28,560,274.64 | 85,205,076.9 | 78,765,553.27 | 44,477,563.25 |
| 六、净利润 | 128,807,591.33 | 555,449,411.27 | 368,906,357.86 | 202,178,809.62 |
| 持续经营净利润 | 128,807,591.33 | 555,449,411.27 | 368,906,357.86 | 202,178,809.62 |
| 归属于母公司股东的净利润 | 128,807,591.33 | 555,449,411.27 | 368,906,357.86 | 202,178,809.62 |
| (一)基本每股收益 | 0.32 | 1.37 | 0.91 | 0.5 |
| (二)稀释每股收益 | 0.32 | 1.37 | 0.91 | 0.5 |
| 九、综合收益总额 | 128,807,591.33 | 555,449,411.27 | 368,906,357.86 | 202,178,809.62 |
| 归属于母公司股东的综合收益总额 | 128,807,591.33 | 555,449,411.27 | 368,906,357.86 | 202,178,809.62 |
| 公告日期 | 2024-04-23 | 2024-03-29 | 2023-10-20 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |